Climb Bio (CLYM)

• Market cap: $634M
• 1 day: -2.29%
• 5 days: 0.64%
• 1 month: 26.2%
• 3 months: 56.72%
• 6 months: 518.99%
• Year to date: 195.47%
• 1 year: 808.2%
• 5 years: -30.31%
• 10 years: -30.31%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

Employees: 29